{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:35:11Z","timestamp":1777944911260,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00520-025-10236-y","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T21:01:03Z","timestamp":1766178063000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cetuximab increases the risk of oral mucositis in radiotherapy-treated head and neck cancer compared to cisplatin: a systematic review of randomized controlled clinical trials"],"prefix":"10.1007","volume":"34","author":[{"given":"Gabriella Alves Juli\u00e3o","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reverton Soares","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarice Lioba","family":"de Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 Alves","family":"Crispim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassia Emanuella N\u00f3brega","family":"Malta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edson Luiz Cetira","family":"Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fl\u00e1vio","family":"da Silveira Bittencourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabr\u00edcio Bitu","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Goberl\u00e2nio","family":"de Barros Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"10236_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.105772","volume":"127","author":"J Routila","year":"2022","unstructured":"Routila J, Qiao X, Weltner J, Rantala J, Carp\u00e9n T, Hagstr\u00f6m J, M\u00e4kitie A, Leivo I, Ruuskanen M, S\u00f6derlund J, Rintala M, Hietanen S, Irjala H, Minn H, Westermarck J, Ventel\u00e4 S (2022) Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma. Oral Oncol 127:105772. https:\/\/doi.org\/10.1016\/j.oraloncology.2022.105772","journal-title":"Oral Oncol"},{"key":"10236_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.01.059","author":"Y Yu","year":"2024","unstructured":"Yu Y et al (2024) A phase II trial of xevinapant in combination with post-operative cisplatin and radiotherapy for high risk head and neck cancer. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.01.059","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10236_CR3","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s00405-020-06218-x","volume":"278","author":"M Tang","year":"2020","unstructured":"Tang M et al (2020) The evaluation of adding induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: a meta-analysis. Eur Arch Otorhinolaryngol 278:1545\u20131558. https:\/\/doi.org\/10.1007\/s00405-020-06218-x","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"12","key":"10236_CR4","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/j.ejca.2012.04.002","volume":"48","author":"R Morales-Barrera","year":"2012","unstructured":"Morales-Barrera R et al (2012) Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. Eur J Cancer 48(12):1816\u20131821. https:\/\/doi.org\/10.1016\/j.ejca.2012.04.002","journal-title":"Eur J Cancer"},{"key":"10236_CR5","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/S1470-2045(24)00507-2","volume":"25","author":"L Mell","year":"2024","unstructured":"Mell L et al (2024) Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2\/3 trial. Lancet Oncol 25:1576\u20131588. https:\/\/doi.org\/10.1016\/S1470-2045(24)00507-2","journal-title":"Lancet Oncol"},{"key":"10236_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1200\/JCO.20.02072","volume":"39","author":"M Gebre-Medhin","year":"2020","unstructured":"Gebre-Medhin M et al (2020) ARTSCAN III: a randomized phase iii study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer. J Clin Oncol 39:38\u201347. https:\/\/doi.org\/10.1200\/JCO.20.02072","journal-title":"J Clin Oncol"},{"key":"10236_CR7","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.17391","author":"Q Hu","year":"2024","unstructured":"Hu Q et al (2024) Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy. PeerJ. https:\/\/doi.org\/10.7717\/peerj.17391","journal-title":"PeerJ"},{"key":"10236_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00383","author":"M Taberna","year":"2019","unstructured":"Taberna M et al (2019) Cetuximab-containing combinations in locally advanced and recurrent or metastatic head and neck squamous cell carcinoma. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2019.00383","journal-title":"Front Oncol"},{"key":"10236_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2022.03.009","author":"M Swain","year":"2022","unstructured":"Swain M et al (2022) Concurrent cetuximab-based bioradiotherapy versus cisplatin-based chemoradiotherapy in the definitive management of favourable biology human papillomavirus-associated oropharyngeal squamous cell carcinoma: systematic review and meta-analysis. Clin Oncol. https:\/\/doi.org\/10.1016\/j.clon.2022.03.009","journal-title":"Clin Oncol"},{"key":"10236_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/nrclinonc.2015.235","volume":"13","author":"L Hutchinson","year":"2016","unstructured":"Hutchinson L et al (2016) Drug therapy: cetuximab or cisplatin in HNSCC? Nat Rev Clin Oncol 13:66\u201366. https:\/\/doi.org\/10.1038\/nrclinonc.2015.235","journal-title":"Nat Rev Clin Oncol"},{"issue":"27","key":"10236_CR11","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","volume":"32","author":"K Ang","year":"2014","unstructured":"Ang K et al (2014) Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 32(27):2940\u20132950. https:\/\/doi.org\/10.1200\/JCO.2013.53.5633","journal-title":"J Clin Oncol"},{"key":"10236_CR12","doi-asserted-by":"publisher","DOI":"10.4317\/medoral.26237","volume":"29","author":"J De Lima Martins","year":"2023","unstructured":"De Lima Martins J, Borges M, Malta C, Guerra J, Crispim A, Coelho B, Silva L, De Barros Silva P (2023) Risk factors for oral mucositis in patients with solid tumors under treatment with cetuximab: a retrospective cross-sectional study. Med Oral Patol Oral Cir Bucal 29:e248. https:\/\/doi.org\/10.4317\/medoral.26237","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"9","key":"10236_CR13","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.oraloncology.2015.06.008","volume":"51","author":"Xu Tingting","year":"2015","unstructured":"Tingting Xu et al (2015) Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: results of a randomized phase II study. Oral Oncol 51(9):875\u2013879. https:\/\/doi.org\/10.1016\/j.oraloncology.2015.06.008","journal-title":"Oral Oncol"},{"key":"10236_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20054545","author":"M Otsuru","year":"2023","unstructured":"Otsuru M, Yanamoto S, Yamada S, Nakashiro K, Harazono Y, Kohgo T, Nakamura M, Nomura T, Kasamatsu A, Tanaka S, Kirita T, Kioi M, Ogawa M, Sasaki M, Ota Y, Umeda M (2023) Radiotherapy plus cetuximab for squamous cell carcinoma of the oral cavity: a multicenter retrospective study of 79 patients in Japan. Int J Environ Res Public Health. https:\/\/doi.org\/10.3390\/ijerph20054545","journal-title":"Int J Environ Res Public Health"},{"key":"10236_CR15","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s00520-019-04885-z.a","volume":"28","author":"M Nishii","year":"2020","unstructured":"Nishii M, Soutome S, Kawakita A, Yutori H, Iwata E, Akashi M, Hasegawa T, Kojima Y, Funahara M, Umeda M, Komori T (2020) Factors associated with severe oral mucositis and candidiasis in patients undergoing radiotherapy for oral and oropharyngeal carcinomas: a retrospective multicenter study of 326 patients. Support Care Cancer 28:1069\u20131075. https:\/\/doi.org\/10.1007\/s00520-019-04885-z.a","journal-title":"Support Care Cancer"},{"key":"10236_CR16","unstructured":"Al-Saleh K, El-Sherify M, Safwat R, Elbasmy A, Shete J, Hussein A, Nazeeh M, Bedair A (2019) Phase II\/III randomized controlled trial of concomitant hyperfractionated radiotherapy plus cetuximab (anti-EGFR antibody) or chemotherapy in locally advanced head and neck cancer.\u00a0Gulf J Oncolog\u00a01(30):6\u201312"},{"key":"10236_CR17","doi-asserted-by":"publisher","unstructured":"Magrini SM, Buglione M, Corv\u00f2 R, Pirtoli L, Paiar F, Ponticelli P, Petrucci A, Bacigalupo A, Crociani M, Lastrucci L, Vecchio S, Bonomo P, Pasinetti N, Triggiani L, Cavagnini R, Costa L, Tonoli S, Maddalo M, Grisanti S (2016) Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial.\u00a0J Clin Oncol\u00a034(5):427\u2013435.\u00a0https:\/\/doi.org\/10.1200\/JCO.2015.63.1671.v","DOI":"10.1200\/JCO.2015.63.1671.v"},{"key":"10236_CR18","doi-asserted-by":"publisher","unstructured":"Tao Y, Aup\u00e9rin A, Sun X, Sire C, Martin L, Coutte A, Lafond C, Miroir J, Liem X, Rolland F, Even C, Nguyen F, Saada E, Maillard A, Colin-Batailhou N, Thariat J, Guigay J, Bourhis J (2020) Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: the safety phase of a randomised phase III trial GORTEC 2017-01 (REACH).\u00a0Eur J Cancer\u00a0141:21\u201329.\u00a0https:\/\/doi.org\/10.1016\/j.ejca.2020.09.008","DOI":"10.1016\/j.ejca.2020.09.008"},{"key":"10236_CR19","doi-asserted-by":"publisher","unstructured":"Gebre-Medhin M et al (2021) ARTSCAN III: a randomized phase III study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer.\u00a0J Clin Oncol\u00a039(1):38\u201347.\u00a0https:\/\/doi.org\/10.1200\/JCO.20.02072","DOI":"10.1200\/JCO.20.02072"},{"key":"10236_CR20","doi-asserted-by":"publisher","unstructured":"Maddalo M, Borghetti P, Tomasini D, Corv\u00f2 R, Bonomo P, Petrucci A, Paiar F, Lastrucci L, Bon\u00f9 ML, Greco D, Costa L, Pegurri L, Triggiani L, Belgioia L, Desideri I, Grisanti S, Buglione M, Magrini SM (2020) Cetuximab and radiation therapy versus cisplatin and radiation therapy for locally advanced head and neck cancer: long-term survival and toxicity outcomes of a randomized phase 2 trial.\u00a0Int J Radiat Oncol Biol Phys\u00a0107(3):469\u2013477.\u00a0https:\/\/doi.org\/10.1016\/j.ijrobp.2020.02.637","DOI":"10.1016\/j.ijrobp.2020.02.637"},{"key":"10236_CR21","doi-asserted-by":"publisher","unstructured":"Mehanna H et al (2019) Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. The Lancet 393(10166):51\u201360.\u00a0https:\/\/doi.org\/10.1016\/S0140-6736(18)32752-1","DOI":"10.1016\/S0140-6736(18)32752-1"},{"key":"10236_CR22","doi-asserted-by":"publisher","unstructured":"Rischin et al. (2021) Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01) \u2013 a Trans-Tasman Radiation Oncology Group study.\u00a0Int J Radiat Oncol Biol Phys\u00a0111(4):876\u2013886.\u00a0https:\/\/doi.org\/10.1016\/j.ijrobp.2021.04.015","DOI":"10.1016\/j.ijrobp.2021.04.015"},{"key":"10236_CR23","doi-asserted-by":"publisher","unstructured":"Janoray G et al (2020) Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal\/hypopharyngeal cancer: long-term results of the TREMPLIN randomised GORTEC trial.\u00a0Eur J Cancer\u00a0133:86\u201393.\u00a0https:\/\/doi.org\/10.1016\/j.ejca.2020.04.009","DOI":"10.1016\/j.ejca.2020.04.009"},{"key":"10236_CR24","doi-asserted-by":"publisher","unstructured":"Lefebvre JL et al (2013) Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study.\u00a0J Clin Oncol\u00a031(7):853\u2013859.\u00a0https:\/\/doi.org\/10.1200\/JCO.2012.42.3988","DOI":"10.1200\/JCO.2012.42.3988"},{"key":"10236_CR25","doi-asserted-by":"publisher","unstructured":"Merlano MC et al (2020) Phase III randomized study of induction chemotherapy followed by definitive radiotherapy + cetuximab versus chemoradiotherapy in squamous cell carcinoma of the head and neck: the INTERCEPTOR-GONO Study. Oncol 98(11):763\u2013770.\u00a0https:\/\/doi.org\/10.1159\/000507733","DOI":"10.1159\/000507733"},{"key":"10236_CR26","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1200\/JCO.19.01507","volume":"37","author":"C Anderson","year":"2019","unstructured":"Anderson C et al (2019) Phase IIb, randomized, double-blind trial of GC4419 versus placebo to reduce severe oral mucositis due to concurrent radiotherapy and cisplatin for head and neck cancer. J Clin Oncol 37:3256\u20133265. https:\/\/doi.org\/10.1200\/JCO.19.01507","journal-title":"J Clin Oncol"},{"key":"10236_CR27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.5644\/ama2006-124.422","volume":"52","author":"O Kadarullah","year":"2023","unstructured":"Kadarullah O et al (2023) Animal model of cisplatin-induced oral mucositis: dose optimization. Acta Medica Academica 52:188\u2013194. https:\/\/doi.org\/10.5644\/ama2006-124.422","journal-title":"Acta Medica Academica"},{"key":"10236_CR28","doi-asserted-by":"publisher","first-page":"105317","DOI":"10.1016\/j.archoralbio.2021.105317","volume":"133","author":"C Nakatomi","year":"2021","unstructured":"Nakatomi C et al (2021) Cisplatin induces TRPA1-mediated mechanical allodynia in the oral mucosa. Arch Oral Biol 133:105317. https:\/\/doi.org\/10.1016\/j.archoralbio.2021.105317","journal-title":"Arch Oral Biol"},{"issue":"1","key":"10236_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.radonc.2010.11.009","volume":"98","author":"L Walsh","year":"2011","unstructured":"Walsh L et al (2011) Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiother Oncol 98(1):38\u201341. https:\/\/doi.org\/10.1016\/j.radonc.2010.11.009","journal-title":"Radiother Oncol"},{"key":"10236_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","volume":"393","author":"M Gillison","year":"2019","unstructured":"Gillison M et al (2019) Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 393:40\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(18)32779-X","journal-title":"Lancet"},{"issue":"36","key":"10236_CR31","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1200\/JCO.2010.30.6423","volume":"28","author":"A Argiris","year":"2010","unstructured":"Argiris A et al (2010) Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol 28(36):5294\u20135300. https:\/\/doi.org\/10.1200\/JCO.2010.30.6423","journal-title":"J Clin Oncol"},{"key":"10236_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01715-7","author":"C Pulito","year":"2020","unstructured":"Pulito C, Cristaudo A, Porta C, Zapperi S, Blandino G, Morrone A, Strano S (2020) Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res. https:\/\/doi.org\/10.1186\/s13046-020-01715-7","journal-title":"J Exp Clin Cancer Res"},{"key":"10236_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.21294\/1814-4861-2021-20-2-29-36","volume":"20","author":"M Radzhapova","year":"2021","unstructured":"Radzhapova M, Gulidov I, Sevryukov F, Mardynsky Y, Panaseykin Y, Semenov A, Ivanov S, Kaprin A (2021) Chemoradiotherapy for oral cancer using hyperfractionated radiation schedule. Sib J Oncol 20:29\u201336. https:\/\/doi.org\/10.21294\/1814-4861-2021-20-2-29-36","journal-title":"Sib J Oncol"},{"issue":"9","key":"10236_CR34","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.oraloncology.2014.06.010","volume":"50","author":"M Vatca","year":"2014","unstructured":"Vatca M, Lucas J, Laudadio J, D\u2019Agostino R, Waltonen J, Sullivan C, Rouchard-Plasser R, Matsangou M, Browne J, Greven K, Porosnicu M (2014) Retrospective analysis of the impact of HPV status and smoking on mucositis in patients with oropharyngeal squamous cell carcinoma treated with concurrent chemotherapy and radiotherapy. Oral Oncol 50(9):869\u2013876. https:\/\/doi.org\/10.1016\/j.oraloncology.2014.06.010","journal-title":"Oral Oncol"},{"key":"10236_CR35","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.12120","author":"R Ferrari","year":"2024","unstructured":"Ferrari R, Felizardo A, Siqueira L, Abreu L, Araujo D, Ara\u00fajo L, Fernandes T, Lopes C, Peixoto R, Melo B, Costa A, Silva R, Andrade C, Laloni M, Ferrari B, Ferreira C, De Marchi P, Nassib W, Bergerot C (2024) Impact of prophylactic laser therapy on mucositis in patients with head and neck cancer (HNC) undergoing radiotherapy in Brazil. J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2024.42.16_suppl.12120","journal-title":"J Clin Oncol"},{"issue":"6","key":"10236_CR36","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/cbin.11340","volume":"44","author":"M London","year":"2020","unstructured":"London M, Gallo E (2020) Epidermal growth factor receptor (EGFR) involvement in epithelial-derived cancers and its current antibody-based immunotherapies. Cell Biol Int 44(6):1267\u20131282. https:\/\/doi.org\/10.1002\/cbin.11340","journal-title":"Cell Biol Int"},{"issue":"9","key":"10236_CR37","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7(9):715\u2013725. https:\/\/doi.org\/10.1038\/nri2155","journal-title":"Nat Rev Immunol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10236-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-025-10236-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-025-10236-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T08:48:10Z","timestamp":1768985290000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-025-10236-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10236"],"URL":"https:\/\/doi.org\/10.1007\/s00520-025-10236-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This is a systematic review; thus, no ethical approval was needed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}